Korean Pharmas Rush Into Vaccines: SK Chemicals Breaks Ground For Cell-culture Vaccines With Aid From Xcellerex
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's SK Chemicals joined the race with domestic manufacturers for cell-culture vaccine production, breaking ground June 15 for a cell-culture vaccine plant that will produce vaccines via a biomanufacturing platform from U.S.-based vaccine maker Xcellerex starting in the second half of 2014
You may also be interested in...
Mitsubishi Tanabe Pursues Next Generation Vaccines With Medicago, Tag-teams DPP-4 Market With Daiichi Sankyo
Mitsubishi Tanabe hopes to take on GSK’s Rotarix, the only rotavirus vaccine approved in Japan. And in a crowded DPP-4 field, Mitsubishi looks to double its sales efforts following a deal with Daiichi Sankyo.
Korea's Green Cross Strengthens Vaccine Supply Chain For Growing Export Demand
SEOUL - South Korea's leading vaccine producer Green Cross has opened and begun operation of a vaccine egg farm to build up a stable channel for the supply of flu vaccine eggs to the pharma's vaccine plant in Hwasoon, Southwest of Seoul. The company is preparing for increased domestic competition, but it also benefiting from a pickup in foreign demand
Korea's Green Cross Strengthens Vaccine Supply Chain For Growing Export Demand
SEOUL - South Korea's leading vaccine producer Green Cross has opened and begun operation of a vaccine egg farm to build up a stable channel for the supply of flu vaccine eggs to the pharma's vaccine plant in Hwasoon, Southwest of Seoul. The company is preparing for increased domestic competition, but it also benefiting from a pickup in foreign demand